Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics
Ligand Pharmaceuticals Incorporated (LGND)
Today's Latest Price: $85.02 USD
Updated Oct 23 4:00pm
Add LGND to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
LGND Stock Summary
- The price/operating cash flow metric for Ligand Pharmaceuticals Inc is higher than 92.14% of stocks in our set with a positive cash flow.
- With a year-over-year growth in debt of -30.66%, Ligand Pharmaceuticals Inc's debt growth rate surpasses merely 9.36% of about US stocks.
- Ligand Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 43.63%, greater than the shareholder yield of 93.29% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Ligand Pharmaceuticals Inc, a group of peers worth examining would be SEDG, LSCC, QLYS, NUAN, and SMTC.
- LGND's SEC filings can be seen here. And to visit Ligand Pharmaceuticals Inc's official web site, go to www.ligand.com.
LGND Stock Price Chart Interactive Chart >
LGND Price/Volume Stats
| Current price | $85.02 | 52-week high | $127.80 |
| Prev. close | $84.74 | 52-week low | $57.24 |
| Day low | $84.00 | Volume | 700,300 |
| Day high | $88.97 | Avg. volume | 383,513 |
| 50-day MA | $99.70 | Dividend yield | N/A |
| 200-day MA | $100.36 | Market Cap | 1.37B |
Ligand Pharmaceuticals Incorporated (LGND) Company Bio
Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimers disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.
LGND Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $85.02 | $9.59 | -88% |
We started the process of determining a valid price forecast for Ligand Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Ligand Pharmaceuticals Inc ranked in the 12th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Ligand Pharmaceuticals Inc, consider:
- The company's debt burden, as measured by earnings divided by interest payments, is 0.07; that's higher than only 23.35% of US stocks in the Healthcare sector that have positive free cash flow.
- Ligand Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 165 -- greater than 98.43% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -88% |
| 1% | -88% |
| 2% | -88% |
| 3% | -88% |
| 4% | -88% |
| 5% | -88% |
BLFS, PCRX, BSX, ELAN, and EW can be thought of as valuation peers to LGND, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...